Cartalax – 20mg

Description

For Research Use Only. Supplied exclusively for laboratory research. Not for human or veterinary use.

Cartalax 20mg Research Peptide

Cartalax is the short peptide Ala-Glu-Asp, also described in research literature as AED or T-31. Zentra Brands is preparing a 20mg vial format for laboratory research. Batch testing is currently in progress; release is subject to review of the matching analytical results.

Technical Specifications

Reference chemistry describes the peptide, not a completed analysis of this batch. Consult the final batch documentation for confirmed identity, composition and analytical results.

Batch Testing and Documentation

The matching certificate of analysis will be added after testing is completed and reviewed. We do not substitute another compound’s report or another batch’s purity result. Available reports can be checked in the Batch Verification and COA Centre.

Research Context

Cartalax (AED; Ala-Glu-Asp) has been investigated in experimental research relating to cartilage biology, mesenchymal stem-cell regulation and age-associated cellular processes. Published research discusses AED as a component of a cartilage-derived peptide complex and reports effects on gene expression in models of mesenchymal stem-cell ageing, including pathways associated with cellular metabolism and differentiation.

Research literature also examines short peptides in the context of chondrogenic differentiation — the process by which mesenchymal stem cells develop toward cartilage-forming chondrocytes — and discusses AED alongside experimental observations involving cartilage-related and fibroblast cell models. These findings are preclinical and do not establish cartilage repair, therapeutic efficacy or clinical benefit in humans.

Cartalax is AED, a three-amino-acid peptide, and is distinct from Epithalon (AEDG). Zentra Brands provides this material exclusively for laboratory research and provides no medical, therapeutic or personal-use dosing guidance.

Storage and Laboratory Handling

Follow the batch-specific supplier instructions and your laboratory’s validated procedures. Protect the sealed material from moisture and contamination. Record the lot identifier when preparing experiments and consult the research peptide storage guide for general background. No product-specific shelf life is claimed while batch documentation is pending.

Cartalax Research FAQs

What is Cartalax?

Cartalax is the AED tripeptide, consisting of alanine, glutamic acid and aspartic acid.

What size is this product?

This listing is for one 20mg vial; the value identifies nominal vial content, not a usage instruction.

Is the batch testing complete?

No. Testing is in progress. The batch report must be reviewed before this product is released.

Is Cartalax the same as Epithalon?

No. They have different peptide sequences and must not be treated as interchangeable research materials.

Is this for human or veterinary use?

No. It is intended exclusively for laboratory research.

Selected Research and Reference Sources

• Peptide Regulation of Gene Expression: A Systematic Review — includes Cartalax (AED) in its review of short-peptide research and discusses regulation of cartilage-related cellular functions and gene-expression models.
• Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers — identifies Cartalax (AED) and summarizes its reported experimental research context.
• Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro — additional AED cell-model research.
• AED reference chemistry — Cayman Chemical

External references describe research or reference materials; they are not certificates for the Zentra Brands batch.

Research Resources

• Batch verification and analytical reports
• Epithalon research product information
• Research peptide catalogue

For research use only. Not for human or veterinary use.